Purchase this article with an account.
Faruque Ghanchi, Corinne Fulcher, Sobha Sivaprasad, Konstantinos Balaskas, Richard Peter Gale, Gabriella De Salvo, James S Talks, Andrew Lotery, Ian A Pearce; Acceptability of OCT Angiography: A multicentre OCT Angiography NEtwork (OCTANE) study.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3477.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Spectral Domain OCT angiography (OCT-A) provides high resolution imaging of the chorio-retinal vasculature and may be used as a non-invasive alternative to diagnostic retinal dye angiography. The OCTANE study is first study to define feasibility of using OCT-A within a busy, real-world clinical setting. The purpose was to define acceptability of OCTA by patients and technicians in routine clinical practice.
Following ethical approval, patients attending for the care of a retinal condition at one of seven UK hospitals were randomly recruited. 284 patients underwent standardised imaging including OCT-A with Spectralis (Heidelberg Engineering, Germany). Patient and technician feedback was collected on a standardised questionnaire, designed for this study. Analysis was divided into “patient” and “technician” acceptability. 51 patients were excluded due to incomplete data, and a further 5 were excluded from the patient analysis due incomplete questionnaire. Thus 233 patients were included in the patient feasibility analysis and 238 in the technician feasibility analysis.
The mean age of patients was 64.2 years (range 22 – 94 years) and 47.5% were female. 30% of patients had age-related macular degeneration, 20% had diabetic eye disease, 10% had retinal vein occlusion and 40% other retinal pathology (Fig. 1). Visual acuity across all eyes tested ranged from Snellen acuity of 6/3 to no perception of light. From the patient analysis (n=233), 85.8% of patients found OCT-A to be acceptable with 96.6% reporting that they would have the test again. 92.3% also agreed that the test was comfortable. Amongst the technician analysis (n=238), there were no reported problems in 79.8% of cases (Fig. 2). Common difficulties reported were due to poor patient fixation and long acquisition time. No adverse events were reported.
In diverse patient population Spectralis OCT-A was found to be well accepted by both patients and technicians in routine clinical practice at seven UK hospitals. OCT-A has potential to be a routine clinical test in retina practice.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
Figure 1: Patient diagnosis
Figure 2. Patient and Technician feedback
This PDF is available to Subscribers Only